Skip to content

Annexon ANNX Current ratio

Current ratio at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.6×-1.4×
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
29.3×+13.3×
Omeros logo
OmerosOMER
+1.9×
Vor Biopharma logo
Vor BiopharmaVOR
31.1×+27.3×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
10.3×-1.3×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
10.2×+7.0×

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×

Where this comes from

Calculated from Annexon’s reported figures.

Based on the most recent quarter.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's current ratio?
Annexon (ANNX) reported current ratio of 6.4× in Q1 2026.
How has Annexon's current ratio changed year-over-year?
Annexon's current ratio decreased by 20.5% year-over-year, from 8× to 6.4×.
What is the long-term trend for Annexon's current ratio?
Over 5 years (2020 to 2025), Annexon's current ratio has grown at a -29.8% compound annual growth rate (CAGR), from 33.3× to 5.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.